Charco Neurotech

Charco Neurotech is a private, commercial-stage medical device company founded in 2019 in London. It has developed and launched the CUE1/CUE1+, a wearable device that uses pulsed cueing and high-frequency focused vibrotactile stimulation to manage Parkinson's disease symptoms. With over 3,000 users, pilot data suggests clinically significant improvements in motor scores. The company operates on a direct-to-consumer/medical device sales model and is supported by design, engineering, and clinical expertise.

Wearable device delivering focused, high-frequency vibrotactile stimulation and pulsed cueing to the peripheral nervous system to modulate sensory processing and alleviate motor symptoms.

Competes in the non-invasive neuromodulation and digital therapeutic space for Parkinson's. Potential competitors include companies developing wearable cueing devices, other vibrotactile stimulation technologies, and broader digital health platforms for neurological conditions. It differentiates through its specific focused vibration mechanism, discreet design, and integrated app for medication reminders and symptom tracking.